截至2025年6月30日，公司有409个药物临床研究项目在境内开展，237个项目在境外开展，其中有194个 项目在境外(主要于南韩、澳大利亚、东南亚、欧洲及美国)进行单一区域临床试验。有43个项目在亚太 地区、北美洲、欧洲及非洲进行多区域临床试验，涉及治疗领域包括肿瘤、呼吸、心血管、内分泌、风 湿免疫、感染、罕见疾病及疫苗等。 放眼未来，公司将持续拥抱监管变革、技术创新和全球拓展，持续完善和打造一体化临床研发服务平 台，提升端到端的一站式服务能力。公司将通过建立特定治疗领域业务团队，不断拓展跨国药企和国内 大型药企客户业务；通过可持续增长和潜在收购提升公司在美国和欧洲等地的商务和运营能力；同时将 加强建设与行业各方的互惠协作关系，进一步巩固公司在国内市场的优势地位，提升全球市场份额，力 求实现业务的可持续发展和业绩增长，为股东持续创造回报。追加内容 本文作者可以追加内容哦 ! 格隆汇8月28日丨泰格医药(03347.HK)公告，截至2025年6月30日止6个月中期业绩，公司实现收入人民 币32.5亿元，同比下降3.2%。公司拥有人应占利润同比减少22.2%至报告期间的人民币3.83亿元。每股 盈利0.45人民 ...

杭州泰格医药科技股份有限公司（以下简称"公司"）第五届监事会第十一次会议于2025 年8月28日在杭州市滨江区聚工路19号盛大科技园A座19层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2025年8月14日以电话、电子邮件方式向全体 监事发出。会议应到监事3人，实到监事3人。本次会议由监事会主席张炳辉先生主持。本 次会议的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会监事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于公司2025年半年度报告全文、报告摘要及2025年半年度 业绩公告的议案》。 证券代码：300347 证券简称：泰格医药 公告编码（2025）034 号 杭州泰格医药科技股份有限公司 第五届监事会第十一次会议决议公告 公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 与会监事一致认为：公司2025年半年度报告全文、报告摘要及2025年半年度业绩公告 符合法律、法规、中国证监会、深圳证券交易所和香港联合交易所的相关规定，公司报告 内容真实、准确、完整地反映了公司2025年半 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）033 号 杭州泰格医药科技股份有限公司 第五届董事会第十八次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十八次会议于2025 年8月28日在杭州市滨江区聚工路19号盛大科技园A座19层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2025年8月14日以电话、电子邮件方式向全体 董事发出。会议应到董事7人，实到董事7人。本次会议由公司董事长叶小平先生主持。本 次会议的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于公司2025年半年度报告全文、报告摘要及2025年半年度 业绩公告的议案》； 公司2025年半年度报告全文及其摘要详见中国证监会指定的创业板信息披露网站， 2025年半年度业绩公告详见香港联合交易所信息披露网站。 表决结果：同意7票，反对0票，弃权0票。 二、审议并通过《关于减少注册资 ...

杭州泰格医药科技股份有限公司 2025 年半年度报告全文 杭州泰格医药科技股份有限公司 2025 年半年度报告 2025 年 8 月 29 日 1 杭州泰格医药科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人曹晓春、主管会计工作负责人杨成成及会计机构负责人(会计 主管人员)夏江梅声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 无 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第二节 | 公司简介和主要财务指标 10 | | | --- | --- | --- | | 第三节 | 管理层讨论与分析 13 | | | 第四节 | 公司治理、环境和社会 | 32 | | 第五节 | 重要事项 | 34 | | 第六节 | 股份变动及股东情况 40 | | | 第七节 | 债券相关情况 47 | | | 第八节 | 财务报告 | 48 | 杭州泰格医药科技 ...

Core Insights - The company reported a revenue of 3.25 billion yuan for the six months ending June 30, 2025, representing a year-on-year decrease of 3.21% [1] - Net profit attributable to shareholders was 383 million yuan, down 22.22% year-on-year, with basic earnings per share at 0.45 yuan [1] Revenue Breakdown - Revenue from the domestic business in mainland China decreased by 9.2% compared to the same period in 2024, primarily due to a decline in the clinical trial technical services segment [1] - Conversely, revenue from overseas operations increased by 4.4% year-on-year, driven by the company's ongoing global expansion, enhanced service capabilities, and rapid growth in overseas clinical trial services [1]

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the domestic market while showing growth in international operations [1]. Financial Performance - The company achieved operating revenue of 3.25 billion yuan, a year-on-year decrease of 3.21% [1]. - Net profit attributable to shareholders was 383 million yuan, reflecting a year-on-year decrease of 22.22% [1]. - Basic earnings per share were 0.45 yuan [1]. Regional Performance - Revenue from the domestic market decreased by 9.2% compared to the same period in 2024, primarily due to a decline in the clinical trial services segment [1]. - Conversely, revenue from overseas operations increased by 4.4% year-on-year, driven by the company's efforts to enhance global presence, improve service capabilities, and expand international clinical trial services [1].

Core Viewpoint - The company reported a decline in revenue and profit for the six months ending June 30, 2025, while continuing to expand its clinical research projects both domestically and internationally [1][2] Financial Performance - The company achieved revenue of RMB 3.25 billion, a year-on-year decrease of 3.2% [1] - Profit attributable to shareholders decreased by 22.2% to RMB 383 million during the reporting period [1] - Earnings per share were RMB 0.45 [1] - The board decided not to declare any interim dividend for the six months ending June 30, 2025 [1] Clinical Research Projects - As of June 30, 2025, the company had 409 clinical research projects underway domestically and 237 projects internationally [1] - Among the international projects, 194 were conducting single-region clinical trials primarily in South Korea, Australia, Southeast Asia, Europe, and the United States [1] - The company also had 43 projects conducting multi-region clinical trials across Asia-Pacific, North America, Europe, and Africa, covering various therapeutic areas including oncology, respiratory, cardiovascular, endocrine, rheumatology, infectious diseases, rare diseases, and vaccines [1] Future Strategy - The company aims to embrace regulatory changes, technological innovations, and global expansion to enhance its integrated clinical research service platform [2] - Plans include establishing specialized business teams in specific therapeutic areas to expand client relationships with multinational and large domestic pharmaceutical companies [2] - The company seeks sustainable growth and potential acquisitions to enhance its business and operational capabilities in the U.S. and Europe [2] - Strengthening collaborative relationships within the industry is a priority to consolidate its domestic market position and increase global market share [2] - The goal is to achieve sustainable business development and performance growth, continuously creating returns for shareholders [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 截 至2025年6月30日止六個月之 中期業績公告 財務摘要 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） | | | | | 截 | | | 至6月30日止六個月 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 2025年 | | | | | | 2024年 | | | | 變 動（2） | | 人民幣百萬元 | | | | | | | 人民幣百萬元 | | | | | | | | （未 | （未 經 ...

Group 1 - The core viewpoint of the article highlights the overall poor performance of Hong Kong's biopharmaceutical stocks, with significant declines in major companies such as WuXi AppTec, Tigermed, and King’s Ray Biotech [1] - U.S. President Trump announced plans to reduce drug prices to 1/1400 to 1/1500 of current prices and to impose tariffs on pharmaceuticals, which could create volatility in the global pharmaceutical industry [1] - The Chinese biopharmaceutical sector faces both opportunities and challenges due to these developments, with potential short-term market fluctuations driven by uncertainty, particularly for businesses exposed to the U.S. market [1] Group 2 - In the long term, China's pharmaceutical industry may leverage its innovation and supply chain advantages to find new growth opportunities in the global pharmaceutical landscape, especially in areas like CDMO and internationalization of innovative drugs [1] - The article lists the latest prices and percentage changes for various biopharmaceutical stocks, indicating a general downward trend across the sector [1]

Core Viewpoint - Tiger Med's stock price has shown fluctuations, with a year-to-date increase of 23.82% and a recent decline over the past 20 days, indicating mixed market sentiment towards the company [1][2]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1]. - The main business segments include clinical trial services (49.91% of revenue), clinical trial technical services (48.13%), and other services (1.95%) [1]. Financial Performance - For the first quarter of 2025, Tiger Med reported a revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Structure - As of March 31, 2025, Tiger Med had 53,800 shareholders, an increase of 1.95% from the previous period. The top shareholders include various mutual funds and ETFs, with notable changes in holdings among major institutional investors [3].